Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Neurobiol Dis. 2012 Jan 24;46(1):180–189. doi: 10.1016/j.nbd.2012.01.006

Fig. 1.

Fig. 1

Pretreatment with EGb 761 and its components reduces damage from stroke. (A) Schematic diagram of the experimental protocol. Mice were orally administered EGb 761 (100 mg/kg; n=9), BB (6 mg/kg; n=8), GA (6 mg/kg; n=6), GB (6 mg/kg; n=7), TFM (10 mg/kg; n=10), or vehicle control (n=4) once daily for 7 days; tMCAO was induced on day 8; mice were evaluated for neurologic deficit score (NDS) and sacrificed on day 10. (B) Compared with vehicle-treated controls, groups pretreated with EGb 761, BB, and GB had significantly lower NDS, (D) and those pretreated with EGb 761, BB, GA, and GB had significantly smaller infarct volumes. (C) Representative brain sections of mice showing infarct volumes of different treatment groups. Data are expressed as means ± SEM; p 0.05 vs. vehicle.